Viking Therapeutics, Inc.
VKTX
$23.94
$0.341.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 49.28M | 42.81M | 37.92M | 37.46M | 37.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 150.92M | 133.97M | 124.68M | 114.36M | 100.83M |
| Operating Income | -150.92M | -133.97M | -124.68M | -114.36M | -100.83M |
| Income Before Tax | -109.96M | -99.15M | -96.75M | -93.72M | -85.90M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -109.96 | -99.15 | -96.75 | -93.72 | -85.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -109.96M | -99.15M | -96.75M | -93.72M | -85.90M |
| EBIT | -150.92M | -133.97M | -124.68M | -114.36M | -100.83M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.01 | -0.94 | -0.94 | -0.93 | -0.92 |
| Normalized Basic EPS | -0.63 | -0.59 | -0.59 | -0.58 | -0.57 |
| EPS Diluted | -1.01 | -0.94 | -0.94 | -0.93 | -0.92 |
| Normalized Diluted EPS | -0.63 | -0.59 | -0.59 | -0.58 | -0.57 |
| Average Basic Shares Outstanding | 436.10M | 424.70M | 413.64M | 402.26M | 377.15M |
| Average Diluted Shares Outstanding | 436.10M | 424.70M | 413.64M | 402.26M | 377.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |